CliffBio
biologic

Abecma

idecabtagene vicleucel

Loss of exclusivityApril 2036projected — 12-year biologic exclusivity estimate
CompanyCelgene Corporation, a Bristol-Myers Squibb Company

Drug detail

Brand nameAbecma
Active ingredientidecabtagene vicleucel
Strength300 to 510 X 10^6 CHIMERIC ANTIGEN RECEPTOR (CAR)-POSITIVE T CELLS
Dosage formSuspension
RouteIntravenous
ModalityBiologic
FDA approvalApril 2024
Marketing statusRx

More from Celgene Corporation, a Bristol-Myers Squibb Company

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Abecma patent cliff — loss of exclusivity April 2036 | CliffBio